BRAF and female reproductive organ cancer: Similar results were also reported for AZD5363 [29], although exclusive PIK3CA mutations did not correlate with increased response in another study in breast or gynecological cancer patients where concurrent mutations in KRAS, NRAS, HRAS, or BRAF were excluded [23].